Cadila Healthcare closed 2.4% higher at Rs.342.80 on BSE after it was reported that the company’s subsidiary Zydus Cadila entered into a sub-licensing agreement with the Medicines Patent Pool for Hepatitis C medicine, Daclatasvir.
The scrip opened at Rs. 335.7 and touched a high and low of Rs. 348 and Rs. 332.5 respectively. A total of 1401733(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 34259.55 crore.
The BSE group 'A' stock of face value Rs. 1 touched a 52 week high of Rs. 454.4 on 23-Oct-2015 and a 52 week low of Rs. 295.5 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs. 336.65 and Rs. 319.35 respectively.
The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 13.85 % and 11.36 % respectively.
The stock traded above its 200 DMA.
The scrip opened at Rs. 335.7 and touched a high and low of Rs. 348 and Rs. 332.5 respectively. A total of 1401733(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 34259.55 crore.
The BSE group 'A' stock of face value Rs. 1 touched a 52 week high of Rs. 454.4 on 23-Oct-2015 and a 52 week low of Rs. 295.5 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs. 336.65 and Rs. 319.35 respectively.
The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 13.85 % and 11.36 % respectively.
The stock traded above its 200 DMA.
No comments:
Post a Comment